KNSA Live signals | Maximize Profits with Getagraph.com

SELL 103103 min ago

@ $19.84

Issued: 13 Feb 2024 @ 15:47

Return: -9.98%

Previous signal: Feb 12 - 13:31

Previous signal: Buy

Return: -4.34 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	371 501
Average Volume	366 937
Market Cap	1.26B
EPS	$0 ( 2024-04-23 )
Next earnings date	( $-0.140 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	89.30
ATR14	$0.0300 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Patel Sanj K	Buy	129 750	Share Option
2024-04-08	Patel Sanj K	Buy	9 992	Class A Common Share
2024-04-08	Patel Sanj K	Sell	4 075	Class A Common Share
2024-04-04	Patel Sanj K	Buy	24 950	Restricted Share Unit
2024-04-08	Patel Sanj K	Sell	9 992	Restricted Share Unit

INSIDER POWER
24.61
Last 100 transactions
Buy: 576 726 \| Sell: 364 070

Volume Correlation

Long: 0.24 (neutral)

Short: 0.01 (neutral)

Signal:(55.928) Neutral

Kiniksa Pharmaceuticals Correlation

10 Most Positive Correlations
CSSEP	0.955
EVLO	0.953
GOOD	0.952
SIRI	0.951
ORPH	0.95
ALXO	0.95
NAKD	0.95
AYTU	0.949
LSXMA	0.948
LSXMK	0.948

10 Most Negative Correlations
CPAQ	-0.966
HERA	-0.966
TBSA	-0.965
AGGR	-0.965
LGAC	-0.965
ACQR	-0.964
APXI	-0.964
KAII	-0.964
FICV	-0.963
HERAU	-0.963

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kiniksa Pharmaceuticals Correlation - Currency/Commodity

-0.41
( neutral )

-0.44
( neutral )

0.00
( neutral )

-0.28
( neutral )

0.85
( strong )

0.08
( neutral )

Kiniksa Pharmaceuticals Financials

Annual	2023
Revenue:	$270.26M
Gross Profit:	$179.22M (66.31 %)
EPS:	$0.200

Q1	2024
Revenue:	$79.86M
Gross Profit:	$59.06M (73.95 %)
EPS:	$-0.000300

Q4	2023
Revenue:	$83.40M
Gross Profit:	$56.64M (67.91 %)
EPS:	$0.360

Q3	2023
Revenue:	$67.05M
Gross Profit:	$40.65M (60.63 %)
EPS:	$-0.200

Financial Reports:

No articles found.

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.